Ischemic heart disease: Metabolic approaches to management

Pauly, Daniel F.; Pepine, Carl J.

doi:10.1002/clc.4960270802

Cited by 17 publications

(22 citation statements)

References 17 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Medical history (hypertension, diabetes, smoking, duration of coronary artery disease), angiographical findings before PTCA and properties of the process (size of the balloon, highest pressure and time for total balloon inflation, stent diameter) were similar for all patients. Criteria for hypertension were systolic and diastolic blood pressures of 135 mmHg and 85 mmHg, respectively; for diabetes, clinical manifestions of diabetes mellitus and a fasting glucose concentration of 126 mg/dl; for smoking, cigarette smoking 10 pack-years (Pauly and Pepine 2004). Because serum NO levels can be heavily influenced by dietary nitrogen intake, we fixed the dietary nitrogen intake to 1 g/kg/day of protein per meal during the week prior to PTCA.…”

Section: Patientsmentioning

confidence: 99%

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Kuralay

Altekin

Yazlar

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Percutaneous transluminal coronary angioplasty (PTCA) has been recognized as a reliable treatment procedure for acute reversible ischemia and reperfusion. Ischemic reperfusion cycle in PTCA leads to the systemic inflammation and extensive tissue injury by the production of reactive oxygen species including nitric oxide (NO) radicals. In patients with coronary artery disease, undergoing PTCA, the effects of trimetazidine (TMZ), a piperazine-derivative anti-anginal drug, were studied on several indirect markers of systemic inflammatory response: tumor necrosis factor-α (TNF-α ), C-reactive protein (CRP) and NO products (nitrite and nitrate). Patients (n = 11 each group) were untreated or pre-treated with TMZ (20 mg per orally three times a day), begun three days prior to PTCA, and marker levels were measured before the start of TMZ therapy (baseline), just before PTCA (0 hr), and 4, 24, and 48 hrs after PTCA. The baseline levels of markers were not significantly different between the untreated and pre-treated patients. In contrast, all parameters were lower in the TMZtreated group than those in the matched control group in the pre-and post-angioplasty periods. Interestingly, in the TMZ group, CRP and nitrite levels were significantly lower than in the control group at each time point of the pre-and post-angioplasty periods, but the TNF-α levels were significantly decreased only in the post-angioplasty period. Preprocedural treatment with oral TMZ for three days significantly suppressed the elevation of inflammatory markers before and shortly after PTCA. We suggest the usefulness of TMZ in preventing inflammatory cardiovascular events after PTCA.trimetazidine; percutaneous transluminal coronary angioplasty; C-reactive protein; nitric oxide; tumor necrosis factor-α .

show abstract

Section: Patientsmentioning

confidence: 99%

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Kuralay

Altekin

Yazlar

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…29 Under normal conditions in the absence of ischemia, cardiomyocytes derive 60%-70% of their energy requirement from fatty acid oxidation because fatty acids produce more ATP than glucose oxidation, but this occurs at the expense of higher oxygen requirement. Glucose is usually a secondary source of energy for the myocardium.…”

Section: Novel Pharmacological Strategiesmentioning

confidence: 99%

Newer Therapies for Management of Stable Ischemic Heart Disease With Focus on Refractory Angina

Singh

Arora²

2016

American Journal of Therapeutics

View full text Add to dashboard Cite

Ischemic heart disease remains a major public health problem nationally and internationally. Stable ischemic heart disease (SIHD) is one of the clinical manifestations of ischemic heart disease and is generally characterized by episodes of reversible myocardial demand/supply mismatch, related to ischemia or hypoxia, which are usually inducible by exercise, emotion, or other stress and reproducible-but which may also be occurring spontaneously. Improvements in the treatment of acute coronary syndromes along with increasing prevalence of cardiovascular risk factors, including diabetes and obesity, have led to increasing population of patients with SIHD. A significant number of these continue to have severe angina despite medical management and revascularization procedures performed and may progress to refractory angina. This article reviews the newer therapies in the treatment of SIHD with special focus in treating patients with refractory angina.

show abstract

“…8,9 Fatty acid oxidation is dominated or enhanced in the hearts of human patients and in animal models of diabetes (type I or II) and ischemic heart disease (e.g., angina pectoris). 10,11 A growing body of evidence points to the therapeutic value of reducing fatty acid metabolism for ischemic heart diseases, [12][13][14][15][16] and numerous approaches to either inhibit fatty acid oxidation or stimulate glucose oxidation have been proposed which may protect the heart from fatty acid-induced ischemic damage. 4,17 Several researches suggest that inhibition of fatty acid oxidation by inhibiting CPT-I activity through increasing malonylCoA levels with MCD inhibitors would result in a novel and perhaps a much safer method to the prophylaxis and treatment of ischemic heart diseases, 8,9 compared with other known small-molecule CPT-I inhibitors, which has been proved to be beneficial during myocardial ischemia and reperfusion.…”

Section: Introductionmentioning

confidence: 99%

QSAR study of malonyl‐CoA decarboxylase inhibitors using GA‐MLR and a new strategy of consensus modeling

Lei

Liu

et al. 2008

J Comput Chem

View full text Add to dashboard Cite

Quantitative structure-activity relationship (QSAR) of a series of structural diverse malonyl-CoA decarboxylase (MCD) inhibitors have been investigated by using the predictive single model as well as the consensus analysis based on a new strategy proposed by us. Self-organizing map (SOM) neural network was employed to divide the whole data set into representative training set and test set. Then a multiple linear regressions (MLR) model population was built based on the theoretical molecular descriptors selected by Genetic Algorithm using the training set. In order to analyze the diversity of these models, multidimensional scaling (MDS) was employed to explore the model space based on the Hamming distance matrix calculated from each two models. In this space, Q(2) (cross-validated R(2)) guided model selection (QGMS) strategy was performed to select submodels. Then consensus modeling was built by two strategies, average consensus model (ACM) and weighted consensus model (WCM), where each submodel had a different weight according to the contribution of model expressed by MLR regression coefficients. The obtained results prove that QGMS is a reliable and practical method to guide the submodel selection in consensus modeling building and our weighted consensus model (WCM) strategy is superior to the simple ACM.

show abstract

Ischemic heart disease: Metabolic approaches to management

Cited by 17 publications

References 17 publications

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Newer Therapies for Management of Stable Ischemic Heart Disease With Focus on Refractory Angina

QSAR study of malonyl‐CoA decarboxylase inhibitors using GA‐MLR and a new strategy of consensus modeling

Contact Info

Product

Resources

About